Novo Nordisk A/S to Announce the Decision to Enter the Phase 3 Development in Alzheimer's Disease with Oral Semaglutide Call Transcript
Hello, and welcome to Novo Nordisk's Conference Call. (Operator Instructions)
Today, I'm pleased to present Karsten Munk Knudsen, CFO. Please begin your meeting.
/- -
Thank you. Welcome to the Novo Nordisk conference call regarding our decision to initiate Phase III trials within early Alzheimer's disease and an update on our R&D GLP-1 strategy. My name is Karsten Munk Knudsen, and I'm the CFO of Novo Nordisk. And together with me today on the call, I have Mads Krogsgaard Thomsen, our Chief Science Officer; and Martin Lange, our Head of Global Developments.
We will present for around 15 minutes, followed by 30 minutes Q&A.
The next slide, please. As you know, the future is uncertain, and we might be making predictions around the future and especially when we talk about the pipeline, there will inherently be the uncertainties in this case.
Next slide, please. Roughly a year ago, we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |